- Stocks
- Pharma & Healthcare
- Onesource Specialty Pharma
Onesource Specialty Pharma share price
NSE: ONESOURCEPharma & HealthcareBiotechnology
Onesource Specialty Pharma at a glance
Onesource Specialty Pharma (NSE: ONESOURCE) closed at ₹1,378.00 on 22 Oct 2026, up 1.64% on the day. With a market capitalisation of ₹15,796 Cr, it ranks 404th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.
Its return on equity was −1.3% in FY26. Over the past year the share price has fallen 25.1%. Its 52-week range is ₹1,057.00 (30 Jan 2026) to ₹1,925.00 (3 Nov 2025); the last close is 28.4% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹449 Cr (+37.2% year on year) and net profit ₹25 Cr, on a consolidated basis. Promoters held 30.48% of the company as of 30 Jun 2026; 37.23% of promoter shares were pledged.
Key numbers
- Market cap
- ₹15,796 CrRank 404 on NSE
- Price to book
- 2.89×FY26
- EPS (TTM)
- −₹4.24to Q1 FY27
- ROE
- −1.3%FY26
- ROCE
- 0.6%FY26
- Debt to equity
- 0.22FY26
- Net profit margin
- −5.2%FY26
- Book value / share
- ₹508.75FY26
- 52-week high
- ₹1,925.003 Nov 2025
- 52-week low
- ₹1,057.0030 Jan 2026
- 1-year return
- −25.1%
- RSI (14-day)
- 30.6
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +1.64% | −4.1% | −13.8% | −17.2% | −25.1% |
Onesource Specialty Pharma quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹334 Cr | ₹393 Cr | ₹426 Cr | ₹327 Cr | ₹376 Cr | ₹290 Cr | ₹428 Cr | ₹449 Cr |
| Revenue YoY | — | +598.4% | +482.4% | +12.0% | +12.5% | −26.0% | +0.5% | +37.2% |
| Net profit | −₹42 Cr | −₹69 Cr | ₹99 Cr | −₹0 Cr | ₹10 Cr | −₹89 Cr | ₹5 Cr | ₹25 Cr |
| Net profit YoY | — | — | — | — | — | — | −95.3% | — |
| Net margin | −12.6% | −17.5% | 23.1% | −0.1% | 2.8% | −30.6% | 1.1% | 5.6% |
| EPS | −₹3.89 | −₹6.31 | ₹8.61 | −₹0.02 | ₹0.92 | −₹7.74 | ₹0.40 | ₹2.18 |
Onesource Specialty Pharma financials
| Item | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹172 Cr | ₹1,445 Cr | — |
| Operating profit | −₹250 Cr | ₹44 Cr | — |
| Net profit | −₹391 Cr | −₹18 Cr | — |
| EPS (₹) | −₹94.00 | −₹2.00 | — |
| Cash from operations | −₹107 Cr | −₹68 Cr | — |
| Total debt | ₹272 Cr | ₹219 Cr | ₹564 Cr |
| Shareholders' equity | ₹396 Cr | ₹5,881 Cr | ₹5,831 Cr |
Onesource Specialty Pharma shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 34.25% | 29.79% | 29.77% | 29.93% | 30.48% | 30.48% |
| Foreign institutions | 18.54% | 18.69% | 19.39% | 19.24% | 17.50% | 19.19% |
| Domestic institutions | 18.04% | 18.10% | 18.49% | 18.81% | 20.61% | 23.38% |
| Non-institutions | 29.17% | 33.42% | 32.35% | 32.02% | 31.41% | 26.94% |
| Promoter shares pledged | 20.06% | 25.01% | 26.04% | 18.52% | 38.38% | 37.23% |
Onesource Specialty Pharma vs peers
The listed Pharma & Healthcare companies nearest to Onesource Specialty Pharma by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| SHILPAMEDShilpa Medicare | ₹880.90 | +4.74% | +150.3% | ₹16,836 Cr | 70.9 | 9.4% |
| ONESOURCEOnesource Specialty Pharma | ₹1,378.00 | +1.64% | −25.1% | ₹15,796 Cr | — | −1.3% |
| ALIVUSAlivus Life Sciences | ₹1,272.00 | +0.82% | +37.5% | ₹15,576 Cr | 27.7 | 17.2% |
| ERISEris Lifesciences | ₹1,143.60 | +0.76% | −27.9% | ₹15,537 Cr | 25.3 | 15.9% |
| APLLTDAlembic Pharmaceuticals | ₹785.00 | −0.41% | −14.0% | ₹15,357 Cr | 22.9 | 11.2% |
| ASTRAZENAstraZeneca Pharma India | ₹6,056.00 | −0.38% | −33.5% | ₹15,252 Cr | 80.9 | 15.0% |
| SYNGENESyngene International | ₹370.75 | −1.12% | −40.8% | ₹15,037 Cr | 47 | 6.5% |
Ask anything about Onesource Specialty Pharma
Pivot answers on the live chart with evidence you can check, and tests strategies against ONESOURCE's own history. Try: “Why has ONESOURCE moved over the last three months?” · “Backtest a 50-day moving-average crossover on ONESOURCE over five years” · “Compare ONESOURCE with SHILPAMED on margins and valuation”
Frequently asked questions about Onesource Specialty Pharma
What is the share price of Onesource Specialty Pharma today?
Onesource Specialty Pharma (NSE: ONESOURCE) last closed at ₹1,378.00 on 22 Oct 2026. Its 52-week high is ₹1,925.00 and its 52-week low is ₹1,057.00.
What is the market cap of Onesource Specialty Pharma?
Onesource Specialty Pharma's market capitalisation is ₹15,796 Cr (₹15,796 Cr) at the 22 Oct 2026 close, ranking 404th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Onesource Specialty Pharma?
Return on equity was −1.3% in FY26 and return on capital employed was 0.6% in FY26 (consolidated figures).
Is Onesource Specialty Pharma a debt-free company?
No. Onesource Specialty Pharma's debt-to-equity ratio was 0.22 in FY26, with total debt of ₹564 Cr.
What were Onesource Specialty Pharma's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Onesource Specialty Pharma reported revenue of ₹449 Cr, +37.2% year on year, and net profit of ₹25 Cr.
How has Onesource Specialty Pharma stock performed over the last year?
Onesource Specialty Pharma's share price has fallen 25.1% over the past year, −17.2% over three months and −13.8% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Onesource Specialty Pharma?
As of 30 Jun 2026: promoters 30.48%, foreign institutions 19.19%, domestic institutions 23.38%, non-institutions 26.94%. 37.23% of promoter shares were pledged.
Who are Onesource Specialty Pharma's competitors?
The listed Pharma & Healthcare companies closest to Onesource Specialty Pharma by market cap are Shilpa Medicare, Alivus Life Sciences, Eris Lifesciences, Alembic Pharmaceuticals, AstraZeneca Pharma India and Syngene International.
Is Onesource Specialty Pharma a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Onesource Specialty Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ONESOURCE against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with O · all NSE stocks · this page as text